Ahmad Ibrahim, Nabil Chamseddine, Jean El-Cheikh, Colette Hanna, Walid Moukadem, Fady Nasr, Ahmad Younis, Ali Bazarbachi
{"title":"Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective.","authors":"Ahmad Ibrahim, Nabil Chamseddine, Jean El-Cheikh, Colette Hanna, Walid Moukadem, Fady Nasr, Ahmad Younis, Ali Bazarbachi","doi":"10.1007/s44228-022-00017-3","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple myeloma (MM) is a prevalent hematological malignancy. Resource-constrained settings such as the Middle East are particularly burdened by the increasing trends in MM morbidity and mortality in addition to challenges in the management of MM. It thus becomes necessary to identify and address debatable areas of current practice and gaps in the management of MM in the Middle East. With a special focus on the Lebanese situation, the first-line treatment of the very elderly (> 80 years old) is discussed, in addition to the impact of relapse type (biochemical or clinical relapse) on maintenance therapy, the choice of first relapse therapy in relation to maintenance therapy, and the role of MRD in the MM treatment landscape. The need for realistic management guidelines accounting for local resources and expertise, in addition to the reflection of drug accessibility and cost on clinical practice are recognized.</p>","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763519/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Hematology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s44228-022-00017-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Multiple myeloma (MM) is a prevalent hematological malignancy. Resource-constrained settings such as the Middle East are particularly burdened by the increasing trends in MM morbidity and mortality in addition to challenges in the management of MM. It thus becomes necessary to identify and address debatable areas of current practice and gaps in the management of MM in the Middle East. With a special focus on the Lebanese situation, the first-line treatment of the very elderly (> 80 years old) is discussed, in addition to the impact of relapse type (biochemical or clinical relapse) on maintenance therapy, the choice of first relapse therapy in relation to maintenance therapy, and the role of MRD in the MM treatment landscape. The need for realistic management guidelines accounting for local resources and expertise, in addition to the reflection of drug accessibility and cost on clinical practice are recognized.
多发性骨髓瘤（MM）是一种常见的血液恶性肿瘤。在中东等资源有限的地区，多发性骨髓瘤的发病率和死亡率呈上升趋势，管理方面的挑战也日益严峻。因此，有必要确定并解决目前在中东地区 MM 管理中存在争议的领域和差距。本文特别关注黎巴嫩的情况，讨论了高龄老人（大于 80 岁）的一线治疗，以及复发类型（生化或临床复发）对维持治疗的影响、首次复发治疗与维持治疗的关系以及 MRD 在 MM 治疗中的作用。除了药物的可及性和成本对临床实践的影响外，还认识到需要根据当地资源和专业知识制定切合实际的管理指南。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
